Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

US govt seeks new trial in Gilead HIV drug patent case
Pharma
The government lost its high stakes and unusual royalties dispute with the big pharma firm | New status report claims that the court should have allowed the jury to take four inter partes petitions into account.   18 May 2023
FTC sues to bar Amgen from major IP $28bn acquisition
Pharma
The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.   18 May 2023
LabCorp hit with further $100m in DNA test patent case
article
Judge Albright awards punitive damages due to the 'intentional' nature of the infringement | Ravgen fails to secure a three-fold increase on damages awarded by a US jury last year.   16 May 2023
Pharma
The dispute centred on a treatment that helps people adjust their circadian rhythm | Path now clear for generic drug makers to unveil biosimilar versions of the drug.   11 May 2023
Americas
Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.   4 May 2023
Americas
New partner joins from Akin Gump Strauss Hauer & Feld   27 April 2023
article
First chair litigator served six years at the US Patent and Trademark Office.   25 April 2023
Pharma
Canadian firm alleges infringement of patent directed to cosmetic and pharmaceutical formulations | Pharma giant declined a licensing agreement.   20 April 2023
Pharma
Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.   6 April 2023
Americas
As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.   28 March 2023

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.